Background: Previous research examining the association between apolipoprotein E (APOE) gene polymorphism and risk for posttraumatic stress disorder (PTSD) has been inconsistent due to the use of small and select samples. This study examined the relation between APOE genotype and PTSD symptoms in two nationally representative samples of U.S. military veterans. The potential effect of cumulative trauma burden and social support in moderating this association was also evaluated.
factors on mental disorders, as opposed to investigating genetic or environmental influences independently, can substantially further our understanding of the etiology of these conditions (Dick et al., 2015) .
To date, candidate gene studies have identified possible risk alleles mapped to genes implicated in PTSD (Almli, Fani, Smith, & Ressler, 2014) , and several genome-wide significant associations between genes such as AC068718 (rs10170218), RORA (rs8042149), ANKRD55 (rs159572), and ZNF626 (rs11085374) and PTSD Logue et al., 2013; Stein et al., 2016) .
While a growing body of research has evaluated whether polymorphisms in the apolipoprotein E (APOE) gene may contribute to PTSD risk (e.g., Kimbrel et al., 2015; Lyons et al., 2013) , most studies have been small and focused on select samples of trauma survivors (e.g., Vietnam or Iraq/Afghanistan-era veterans). APOE is a protein-coding gene with three functionally different alleles ( 2, 3, 4) , with 3 being the most frequently occurring in the general population. The APOE gene encodes the APOE protein, which plays a role in neuronal repair through its involvement in cholesterol metabolism, and transportation of cholesterol and other lipids to neurons. The APOE 4 allele, however, has been linked to hippocampal atrophy and memory impairment (Pievani et al., 2011; Small, Rosnick, Fratiglioni, & Bäckman, 2004) , reduced synaptic plasticity (Chen, Durakoglugil, Xian, & Herz, 2010) , and a more robust systemic and central nervous system inflammatory response (Lynch et al., 2003) . It has also been associated with greater likelihood of developing several neurological and neuropsychiatric disorders (e.g., Skoog et al., 2015) , especially Alzheimer's disease (Bekris, Yu, Bird, & Tsuang, 2010; Kim, Basak, & Holtzman, 2009 ).
Studies examining the relation between APOE gene and PTSD have been mixed. In a sample of 172 Vietnam veterans, Lyons et al. (2013) found that the presence of an APOE 4 allele was associated with a greater number of PTSD symptoms, but not with PTSD diagnosis. They also observed that 4 carriers with high combat exposure had greatest severity and risk for PTSD. More recently, a study of 859 non-Hispanic black veterans found that each additional APOE 4 allele was associated with 60% greater likelihood of having a PTSD diagnosis and greater severity of PTSD symptoms, and that this finding was only observed among veterans with high levels of combat exposure; these effects were not observed in non-Hispanic white veterans (Kimbrel et al., 2015) . APOE genotype was also unrelated to severity of postdeployment PTSD symptoms in 230 U.S. army soldiers (Dretsch et al., 2015) . Other studies have found the APOE 2 allele, but not 4, to be associated with memory impairment and re-experiencing symptoms of PTSD (Freeman, Roca, Guggenheim, Kimbrell, & Griffin, 2005) , PTSD diagnosis (Kim et al., 2013) , and PTSD symptom severity (Johnson et al., 2015) , which is the opposite of the expectation based on the literature related to Alzheimer's disease.
Gene × environment (G × E) effects of APOE 4 and environmental exposures are also poorly understood. Aside from combat exposure severity (e.g., Kimbrel et al., 2015; Lyons et al., 2013) , it remains unknown whether 4 carrier status may interact with cumulative trauma burden to predict PTSD risk, as has been observed for other genetic polymorphisms (e.g., SLC6A4: Grabe et al., 2009) . Further, no known study has evaluated potentially modifiable moderators of the APOE 4 × trauma burden interaction, such as social support, a robust protective factor for PTSD (Ozer, Best, Lipsey, & Weiss, 2003) . A small number of studies have found low social support to interact with high trauma exposure and genetic risk factors to increase the likelihood of PTSD (Kilpatrick et al., 2007; Lian et al., 2014) , suggesting that high levels of social support may buffer against genetic risk among traumaaffected individuals.
To address these gaps, we analyzed data from two nationally representative samples of trauma-exposed European American (EA) U.S. military veterans to evaluate two aims: (1) examine the relation between APOE 4 carrier status, alone and interactively with cumulative trauma burden, and overall severity of PTSD symptoms and symptom clusters; and (2) determine whether levels of perceived social support may moderate any effects of APOE 4 carrier status and the interaction of 4 × trauma burden in predicting severity of PTSD symptoms.
MATERIALS AND METHODS

Participants
Participants were recruited from a research panel of over 50,000 U.S. Kim et al., 2013; Kimbrel et al., 2015) . One SNP (rs7412) was directly genotyped by the PsychChip array and the other (rs429358)
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was imputed with high-quality score (info = .99). To determine APOE 4 carrier status, we made hard genotype calls of the imputed SNP by applying a posterior genotype probability threshold of .9. There was no evidence of deviation from Hardy-Weinberg expectations for the APOE genotype in either the main (P = .14) or replication (P = .74) sample. A dichotomous variable of 0 versus 1 or 2 APOE 4 alleles was created.
Sociodemographic and military characteristics
Age, sex, household income, education, employment status, marital status, combat veteran status, and number of years of military service were assessed.
Cumulative trauma burden
The Trauma History Screen (THS) assessed lifetime exposure to 13 potentially traumatic events (Carlson et al., 2011) , including child and adult physical and sexual assault, natural disaster, and unexpected loss of a loved one. Events were summed to yield a measure of cumulative trauma burden.
PTSD symptoms
The PTSD Checklist (PCL) was used to assess lifetime and past-month PTSD symptoms based on respondents' worst reported traumatic
was used in the main sample ( = .94) and the DSM-5 version (PCL-5) was administered in the replication sample ( = .95). Veterans were classified as having probable PTSD if their PCL score was ≥50 on the DSM-IV version (Weathers, Litz, Herman, Huska, & Keane, 1993) and ≥38 on the DSM-5 version (Hoge, Riviere, Wilk, Herrell, & Weathers, 2014) . Comparability of the symptom clusters on the two PCL versions was achieved by using the four-factor DSM-IV model of reexperiencing, avoidance, emotional numbing, and hyperarousal symptoms (King, Leskin, King, & Weathers, 1998) , and the DSM-5 model of intrusions, avoidance, negative cognitions and mood, and alterations in arousal and reactivity. Responses on items comprising each symptom cluster were summed to yield severity measures.
Social support
Social support was assessed using a 5-item version of the Medical Outcomes Study Social Support Scale (Amstadter et al., 2010) ; items assessed emotional and instrumental support ( = .90 in main sample;
= .87 in replication sample). Veterans were asked how often each kind of support was available when needed, and items included, "Someone to get together with for relaxation" and "Someone to love and make you feel wanted."
Other psychiatric disorders
The Mini International Neuropsychiatric Interview adapted for selfreport was used to assess lifetime DSM-IV diagnoses of major depressive, alcohol, and drug use disorders (Lecrubier et al., 1997) .
Data analysis
Descriptive statistics were used to summarize sociodemographic, Note. PCL, PTSD Checklist; PTSD, posttraumatic stress disorder. a The DSM-IV version of the PCL was used in the main sample (score range = 17-85) and the DSM-5 version of the PCL was used in the replication sample (score range = 0-80). Table 1 shows sociodemographic, military, and clinical characteristics of trauma-exposed veterans in the main and replication samples. On average, participants in both samples were 62-63 years of age, predominantly male, some college or higher educated, married/cohabitating, retired, had household incomes <$60,000, were noncombat veterans, and spent an average of 7 years in the military. On average, veterans in the samples reported experiencing 3.7-3.8 traumatic life events, with 7.1-10.0% screening positive for lifetime PTSD and 3.5-3.8% for past-month PTSD. Table 2 shows results of analyses evaluating the relation between APOE 4 carrier status, trauma burden, and their interaction, and PTSD symptoms.
RESULTS
In the main sample, APOE 4 carrier status, number of traumas, and their interaction were associated with greater severity of lifetime and past-month PTSD symptoms. cumulative trauma burden (i.e., greater than the median number of three events, n = 602), those with higher levels of perceived social support were less likely to screen positive for current PTSD (2.4% in highest tertile vs. 4.8% in middle tertile vs. 20.5% in lowest tertile; see Fig. 2 ).
In the replication sample, the interaction of APOE 4 carrier status × cumulative trauma burden was significantly associated with lifetime and past-month PTSD symptoms; APOE 4 carrier status was unrelated to these outcomes. Incorporation of an APOE 4 × lifetime traumas × social support interaction term revealed a significant association with lifetime (F = 3.86, P < .001) and past-month (F = 4.55, F I G U R E 2 Prevalence of current PTSD in highly trauma-exposed veterans by 4 carrier status and level of perceived social support in the main sample (n = 602). Note. Current PTSD was identified as a score ≥50 on the DSM-IV version of the PTSD Checklist. Low, moderate, and high levels of perceived social support reflect tertiles of total scores on the 5-item version of the Medical Outcomes Study Social Support Scale. *Statistically significantly greater prevalence than 4 allele carriers with moderate and high levels of perceived social support, 2 (2) = 9.83, P = .007. allele × cumulative trauma burden remained significant for both life-time PTSD symptoms: F = 20.77, P < .001 and F = 36.13, P < .001, respectively; and past-month PTSD symptoms: F = 22.76, P < .001; F = 30.10, P < .001, respectively. In the replication sample, the interaction of e4 allele × trauma burden also remained significant for pastmonth (F = 2.78, P = .003) but not for lifetime (F = 1.30, P = .23) PTSD symptoms. Table 3 shows results of analyses examining the relationship between APOE 4 carrier status, cumulative trauma burden, and the interaction of these variables, and lifetime PTSD symptom clusters. In the main sample, the interaction of APOE 4 carrier status × lifetime traumas was significant for re-experiencing and avoidance symptoms.
In the replication sample, 4 carrier status was associated with greater severity of intrusions; and the interaction of APOE 4 × cumulative trauma burden was significant for intrusion symptoms and alterations in arousal and reactivity.
DISCUSSION
This study examined the association between APOE genotype, trauma exposure, and PTSD symptoms in two contemporary, nationally representative cohorts of EA military veterans. APOE 4 allele carriers reported greater lifetime and past-month PTSD symptoms than noncarriers in the main sample, however, this association was not significant in our replication sample. This finding aligns with a recent meta-analysis supporting an association between 4 carrier status and higher risk for combat-related PTSD (Roby, 2017) . It is possible that the lack of a main effect in the replication sample was due to small sample size, and differences in sociodemographic factors and environmental exposures across samples may also partly account for the inconsistent findings. It is also possible that the discrepancy in findings between the main and replication samples may be attributable in part to the different PCL versions (DSM-IV vs. DSM-5) used; however, after recomputing a PCL-5 summary score by removing the new DSM-5 PTSD symptoms from the PCL-5 such that it more closely aligned with the PCL-S (DSM-IV), the main effect of 4 allele carrier status remained nonsignificant for both lifetime (F = .44, P = .51) and past-month (F = .01, P = .92) symptoms. Further evaluation of a possible association between APOE 4 status and PTSD symptoms is needed in different trauma-exposed samples.
In both samples, APOE 4 carriers with greater trauma burden reported greater lifetime and past-month PTSD symptoms. This finding is consistent with previous work linking 4 allele carrier status to PTSD among veterans with high combat exposure (Lyons et al., 2013; Kimbrel et al., 2015) , and extends it to demonstrate that cumulative trauma burden may also moderate the effect of 4 allele carriage on PTSD symptoms. The APOE 4 allele may hinder the neuronal repair and recovery that is necessary after injury related to extensive stress exposure (Lyons et al., 2013; Kimbrel et al., 2015) . Trauma exposure across the lifespan can deleteriously affect brain structure and function, including reductions in hippocampal volume (Bremner, 2006; Woon, Sood, & Hedges, 2010) and dysregulation of the hypothalamicpituitary-adrenal (HPA) axis (Bremner, 2006; Carpenter et al., 2007; Elzinga et al., 2008) , which can increase risk for developing PTSD symptoms (Gilbertson et al., 2002; Pitman et al., 2012) . APOE 4 allele carriers are similarly at increased risk of several deficits relevant to PTSD, including hippocampal volume loss and amygdala atrophy (den Heijer et al., 2002; Goni et al., 2012) and greater cortisol levels (GillBea et al., 2010) , possibly further exacerbating PTSD vulnerability.
Given that individuals with PTSD are at higher risk of dementia (Yaffe et al., 2010) , it is also possible that the 4 allele contributes to a shared mechanistic pathway for the development of both conditions, or that the development of dementia symptoms plays a role in the 4-PTSD association. For example, a recent study found that Alzheimer's model mice displayed more exaggerated and frequent responses to a PTSD-like induction than control mice (Justice et al., 2015) . Fanselow, 2000; Pievani et al, 2011) , which can maintain re-experiencing/intrusion symptoms. Villasana, Weber, Akinyeke, and Raber (2016) found that mice carrying the 4 allele had higher levels of heme oxygenase-1, a marker of stress, in the hippocampus, and also exhibited greater anxiety-related behaviors and conditioned fear responding. These findings suggest a possible mechanism linking 4 carriage and intrusive symptoms among highly trauma-exposed veterans. Clearly, more research is needed to elucidate mechanisms underlying this association.
Of note, APOE 2 carriage has been found to be associated with memory impairment, more re-experiencing symptoms, and greater overall PTSD symptoms in small samples of humans (Freeman et al., 2005; Johnson et al., 2015) , while stress-exposed mice carrying the 2 allele have been found to have impairments in fear memory extinction (Johnson et al., 2015; Olsen, Agam, Davis, & Raber, 2012) . However, a meta-analysis did not find support for an effect of the e2 variant on risk for combat-related PTSD (Roby, 2017) . Further research in larger samples is needed to help resolve these inconsistent findings regarding APOE genotype and PTSD (Johnson et al., 2015; Rogers & Weeber, 2008 ).
Higher levels of social support were found to be associated with lower PTSD symptoms among APOE 4 allele carriers with greater cumulative trauma burden. This finding adds to a small literature demonstrating an effect of social support in moderating the association between other genetic polymorphisms (Kilpatrick et al., 2007; Lian et al., 2014) and PTSD, depressive symptoms, and suicidal ideation (Chen et al., 2011; Kilpatrick et al., 2007; Kim et al., 2014 Nonetheless, assuming that social support may help buffer against the development of PTSD symptoms, facilitating the enhancement of social support networks (e.g., one-to-one mentorship programs, peer support groups, social/relationship skills interventions, Vet-to-Vet programs) among highly trauma-exposed veterans at elevated genetic risk for PTSD may be an important aspect of prevention initiatives (e.g., Hogan, Linden, & Najarian, 2002; Pietrzak et al., 2009; Resnick & Rosenheck, 2008; Williams, Bambara, & Turner, 2012 ).
The current findings should be considered in light of several limitations. First, PTSD symptoms were assessed via self-report, and it is unclear whether results would be comparable if PTSD symptoms were assessed using a structured clinical interview such as the Clinician Administered PTSD Scale (CAPS). However, statistically significant and large magnitude associations have been observed between total scores on the PCL and on the CAPS (Macdonald, Greene, Torres, Frueh, & Morland, 2013; Monson et al., 2008) . Second, the main sample was larger than the replication sample and different versions of the PCL (i.e., DSM-IV vs. DSM-5) were used in these samples; thus, it is unclear whether differences in patterns of associations between the samples may be related to reduced statistical power or versions of the PCL. Third, the sample was comprised predominantly of male EA veterans. Further research is needed to examine the role of APOE 4 carrier status on risk for PTSD among more diverse samples of veterans and other trauma-affected populations. Fourth, given the strong association between APOE 4 carrier status and poorer cognitive functioning and dementia (e.g., Engelborghs et al., 2003; Wisdom et al., 2011) , it remains to be determined whether cognitive impairment might influence the association between 4 and PTSD, as formal neuropsychological testing was not conducted in this cohort of veterans. Fifth, there have been a number of limitations raised with respect to G × E research with candidate genes, including the lack of replication of some findings, publication bias, and the frequent use of underpowered samples (e.g., Dick et al., 2015) . However, the current study incorporated a number of recommendations made for improving the rigor of G × E studies, including having an adequately powered main sample, an independent replication sample, and a priori selection of candidate genes (i.e., APOE) and environmental factors (i.e., trauma exposure) based on theoretical rationale and existing literature (Dick et al., 2015) . A recent review also recommended additional research examining the effect of positive exposures (i.e., social support) on psychopathology (Leighton, Botto, Silva, Jimenez, & Luyten, 2017) .
CONCLUSION
Results of the present study suggest that APOE 4 carrier status interacts with cumulative trauma burden to predict severity of PTSD symptoms, particularly re-experiencing/intrusive symptoms, in U.S. military veterans. Further, greater social support is associated with lower severity of PTSD symptoms in 4 allele carriers with greater cumulative trauma burden. Further research is needed to examine the complex relationship and mechanistic pathways between APOE genotype, PTSD, and cognitive decline and dementia (Lee et al., 2008; Meziab et al., 2014; Peavy et al., 2007; Yaffe et al., 2010) ; evaluate how APOE and other gene polymorphisms are linked to transdiagnostic aspects of trauma-related psychopathology (e.g., Mota et al., 2015) ; and examine the efficacy of interventions to enhance social support in mitigating PTSD symptoms among at-risk trauma survivors.
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